Modified Fas ligands

Details Modified Fas ligands Modified Fas ligands

1996-11-15

1999-12-14

Eyler, Yvonne

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

530350, 530351, 514 12, 4241851, 536 234, A61K 3800, A61K 3900, C07K 100, C07H 2104

Patent

active

06001962&

ABSTRACT:
The present invention generally provides modified polypeptides which are capable of interacting with the Fas receptor, nucleic acids encoding such polypeptides, cell lines capable of expressing these nucleic acids and secreting the polypeptides, and antibodies that are specifically immunoreactive with these polypeptides. The compositions of the present invention are generally useful for elucidating and modeling aspects of Fas biochemistry in vitro and manipulating Fas biology in vivo.

REFERENCES:
patent: 5731425 (1998-03-01), Brizzard et al.
Pitti et al, "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family" J. Biol. Chem. vol. 271, No. 22, pp. 12687-12690, May 31, 1996.
Hollenbaugh, D. et al., "The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity," Embo J. 11 (12) :4313-4321 (1992).
Korsmeyer, S.J., "Bcl-2 Initiates a New Category of Oncogenes: Regulators of Cell Death," Blood 80(4) :879-886 (1992).
Nagata, S. et al., "The Fas Death Factor," Science 267:1449-1455 (1995).
Ogasawara, J. et al., "Lethal effect of the anti-FAS antibody in mice," Nature 364:806-809 (1993).
Takahashi, T. et al., "Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand," Cell 76:969-976 (1994).
Tanaka, M. et al., "Expression of the functional soluble form of human Fas ligand in activated lymphocytes," Embo J. 14(6) :1129-1135 (1995).
Tanaka, M. et al., "Fas ligand in human serum," Nature Medicine 2(3) :317-322 (1996).
Watanabe-Fukunaga, R. et al., "Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis," Nature 356:314-317 (1992).
Arnold. F. H. "Metal-affinity separations: a new dimension in protein processing" Bio/Technology. vol. 9. pp. 151-156, 1991.

Affiliated with

Also associated with

Rating

Modified Fas ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified Fas ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified Fas ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-864581